Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New drugs for asthma.

P J Barnes1

  • 1Dept of Thoracic Medicine, National Heart and Lung Institute, London, UK.

The European Respiratory Journal
|October 1, 1992
PubMed
Summary
This summary is machine-generated.

New asthma treatments are emerging, including advanced bronchodilators and inhaled corticosteroids. Novel agents targeting inflammation pathways offer future therapeutic options for managing asthma effectively.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucocorticoid resistance in asthma.

American journal of respiratory and critical care medicine·1995
Same author

Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma.

The Journal of experimental medicine·1995
Same author

Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.

Molecular pharmacology·1995
Same author

Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages.

The American journal of physiology·1995
Same author

Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction.

Thorax·1995
Same journal

Beyond the 5th percentile: rethinking diagnostic thresholds in pulmonary function testing.

The European respiratory journal·2026
Same journal

A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction.

The European respiratory journal·2026
Same journal

Risk of cancer and mortality in patients with interstitial lung diseases: Danish cohort study.

The European respiratory journal·2026
Same journal

Proposing a minimal important difference in NTproBNP in pulmonary arterial hypertension.

The European respiratory journal·2026
Same journal

Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis.

The European respiratory journal·2026
Same journal

Decoding the Lymphangioleiomyomatosis (LAM) Niche Microenvironment <i>via</i> Integrative Analysis of Single Cell Multiomics and Spatial Transcriptomics.

The European respiratory journal·2026
See all related articles

Area of Science:

  • Pulmonology and pharmacology, focusing on respiratory diseases.

Background:

  • Asthma treatment relies on existing therapies, but novel drug development is crucial for improved patient outcomes.
  • Current research explores various drug classes to address unmet needs in asthma management.

Purpose of the Study:

  • To review emerging drug classes for asthma treatment.
  • To highlight novel therapeutic agents and future directions in asthma pharmacotherapy.

Main Methods:

  • Literature review of new drug development in asthma.
  • Categorization of novel agents by mechanism of action.

Main Results:

  • Promising long-acting inhaled beta 2-agonists (salmeterol, formoterol) are under development.
  • Novel inhaled corticosteroids, leukotriene antagonists, and 5-lipoxygenase inhibitors show potential.

Related Experiment Videos

  • Future therapies may include bradykinin antagonists, immunomodulators, and cytokine inhibitors.

    • Conclusions:

    • A diverse range of novel pharmacologic agents are in development for asthma.
    • These new drugs offer potential for improved asthma control and treatment strategies.